Sonoma Pharmaceuticals (SNOA) Equity Ratio (2011 - 2025)

Sonoma Pharmaceuticals' Equity Ratio history runs 15 years deep, the most recent figure standing at 0.25 for Q4 2025.

• In Q4 2025, Equity Ratio fell 29.29% year-over-year to 0.25; the TTM figure through Dec 2025 stood at 0.25 (down 29.29% YoY), while the FY2025 annual figure was 0.32, down 22.63% from the prior year.
• Equity Ratio was 0.25 for Q4 2025 at Sonoma Pharmaceuticals, down from 0.27 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.58 in Q3 2021 to a low of 0.25 in Q4 2025.
• Historically, Equity Ratio has averaged 0.41 across 5 years, with a median of 0.41 in 2022.
• The sharpest annual moves came in 2021 and 2022: Equity Ratio plunged 44.51% in 2021, then jumped 41.75% in 2022.
• A 5-year view of Equity Ratio shows it stood at 0.58 in 2021, then tumbled by 30.86% to 0.4 in 2022, then gained by 14.7% to 0.46 in 2023, then fell by 22.17% to 0.36 in 2024, then decreased by 29.29% to 0.25 in 2025.
• The last three Equity Ratio figures came in at 0.25 (Q4 2025), 0.27 (Q3 2025), and 0.28 (Q2 2025), per Business Quant data.